

November 6, 2020

BSE Limited

Corporate Relationship Department
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400 001.

National Stock Exchange of India Limited

Listing Department
Exchange Plaza, Bandra-Kurla Complex,
Bandra (East),
Mumbai – 400 051.

Scrip code: 512529

Symbol: SEQUENT

Dear Sir/ Madam,

Sub: Outcome of Board Meeting held on November 6, 2020 along with Unaudited Standalone & Consolidated Financial Results and Press Release for the quarter and half year ended September 30, 2020

Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at its Meeting held today, *inter-alia*, considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2020. In this regard, kindly find enclosed the following:

1. Unaudited Consolidated Financial Results along with Independent Auditor's Review Report issued by the Statutory Auditors of the Company for the quarter and half year ended September 30, 2020.
2. Unaudited Standalone Financial Results along with Independent Auditor's Review Report issued by the Statutory Auditors of the Company for the quarter and half year ended September 30, 2020.
3. A copy of Press Release and Investors Presentation on Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2020.

The Board Meeting commenced at 12:30 P.M. and concluded at 02:35 P.M.

Thanking you,

Yours faithfully,

For **Sequent Scientific Limited**



Krunal Shah
Company Secretary & Compliance Officer



Encl.: A/a

SeQuent Scientific Limited

Registered Office: 301/A, 'Dosti Pinnacle', Plot No.E7, Road No. 22, Wagle Industrial Area,
Thane(W), Mumbai - 400604, India

Tel: +9122 4111777 | CIN: L99999MH1985PLC036685

<http://www.sequent.in>

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
SeQuent Scientific Limited

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of SeQuent Scientific Limited (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter ended September 30, 2020 and year to date from April 1, 2020 to September 30, 2020 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the **Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity"** issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure I to the Statement.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



SRBC & COLLP

Chartered Accountants

6. The accompanying Statement includes the unaudited interim financial results and other financial information, in respect of:

- Thirteen subsidiaries, whose unaudited interim financial results include total assets of Rs. 1,04,519 lakhs as at September 30, 2020, total revenues of Rs 19,533 lakhs and Rs 39,197 lakhs, total net profit/(loss) after tax of Rs. (156) lakhs and Rs. 167 lakhs, total comprehensive loss of Rs. 1,771 lakhs and Rs. 1,513 lakhs, for the quarter ended September 30, 2020 and the period ended on that date respectively, and net cash (inflows) of Rs. 2,144 lakhs for the period from April 1, 2020 to September 30, 2020, as considered in the Statement which have been reviewed by their respective independent auditors.

The independent auditor's reports on interim financial results of these entities have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiaries is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above.


7. The accompanying Statement includes unaudited interim financial results and other unaudited financial information in respect of:

- Six subsidiaries, whose interim financial results and other unaudited financial information reflect total assets of Rs 2,951 lakhs as at September 30, 2020, and total revenues of Rs 81 lakhs and Rs 156 lakhs, total net loss after tax of Rs. 251 lakhs and Rs. 468 lakhs, total comprehensive loss of Rs. 258 lakhs and Rs. 563 lakhs, for the quarter ended September 30, 2020 and the period ended on that date respectively and net cash inflows of Rs. 22 lakhs for the period from April 1, 2020 to September 30, 2020.

The unaudited interim financial results and other unaudited financial information of the these subsidiaries have not been reviewed by any auditors and have been approved and furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the affairs of these subsidiaries, is based solely on such unaudited interim financial results and other unaudited financial information. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

Our conclusion on the Statement in respect of matters stated in para 6 and 7 above is not modified with respect to our reliance on the work done and the reports of the other auditors and the financial results certified by the Management.

For SRBC & CO LLP
Chartered Accountants
ICAI Firm registration number: 324982E/E300003



per Vikas Kumar Pansari
Partner
Membership No.: 093649
UDIN: 20093649AAAACU5493



Place: Mumbai
Date: November 6, 2020

Annexure I to Auditor's Review Report

Name of the Entity

- | | |
|------------------------------------------|-------------------------|
| 1. SeQuent Research Limited | Wholly Owned Subsidiary |
| 2. Elysian Life Sciences Private Limited | Wholly Owned Subsidiary |
| 3. Alivira Animal Health Limited, India | Wholly Owned Subsidiary |

Including it's following subsidiary:

4. Alivira Animal Health Limited, Ireland

Including its following subsidiaries and sub subsidiaries:

5. Alivira Animal Health Australia Pty Limited
6. Alivira Animal Health UK Limited
7. Alivira Animal Health USA LLC
8. Alivira France S.A.S.
9. Alivira Italy S.R.L.
10. Alivira Saude Animal Brasil Participacoes Ltda
11. Bremer Pharma GmbH
12. Comercial Vila Veterinaria De Lleida S.L.
13. Evance Saude Animal Ltda
14. Fendigo BV
15. Fendigo SA
16. Interchange Veterinária Indústria E Comércio Ltda.
17. Laboratorios Karizoo, S.A.
18. Laboratorios Karizoo, S.A. DE C.V. (Mexico)
19. N-Vet AB
20. Phytotherapeutic Solutions S.L.
21. Provet Veteriner Ürünleri San. Ve Tic. A. Ş.
22. Topkim Topkapi İlaç premiks Sanayi Ve Ticaret A.Ş.
23. Vila Viña Participacions S.L.



Sequent

Proven Ability in Life Sciences

SEQUENT SCIENTIFIC LIMITED

CIN: L99999MH1985PLC036685

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND PERIOD ENDED 30 SEPTEMBER 2020

(₹ in Lakhs)

Sl. No.	Particulars	3 months ended 30-Sep-2020	Preceding 3 months ended 30-Jun-2020	Corresponding 3 months ended in previous period 30-Sep-2019	Year to date figure for current period ended 30-Sep-2020	Year to date figure for previous period ended 30-Sep-2019	Previous year ended 31-Mar-2020
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from operations	34,627.20	31,026.50	28,422.30	65,653.70	56,224.00	1,17,924.40
II	Other income	263.50	154.70	597.00	418.20	728.20	1,008.90
III	Total income (I+II)	34,890.70	31,181.20	29,019.30	66,071.90	56,952.20	1,18,933.30
IV	Expenses						
	(a) Cost of materials consumed	13,726.30	14,266.50	12,253.80	27,992.80	24,256.50	50,869.20
	(b) Purchases of stock-in-trade	3,840.50	3,234.20	1,831.30	7,074.70	4,058.70	8,889.00
	(c) Changes in inventories of finished-goods, stock-in-trade and work-in-progress	503.20	(1,557.40)	990.90	(1,054.20)	1,072.10	746.90
	(d) Employee benefits expense	4,332.50	4,414.30	4,079.90	8,746.80	8,051.30	16,505.90
	(e) Finance costs	736.10	764.50	783.70	1,500.60	1,678.20	3,571.40
	(f) Depreciation and amortisation expenses	1,330.30	1,302.70	1,246.40	2,633.00	2,447.60	5,062.20
	(g) Other expenses	6,585.50	5,567.30	5,550.50	12,152.80	11,225.30	23,881.20
	Total expenses	31,054.40	27,992.10	26,736.50	59,046.50	52,789.70	1,09,525.80
V	Profit before tax and exceptional items (III-IV)	3,836.30	3,189.10	2,282.80	7,025.40	4,162.50	9,407.50
VI	Exceptional items (Refer note 7)	903.90	-	-	903.90	-	-
VII	Profit before tax (V-VI)	2,932.40	3,189.10	2,282.80	6,121.50	4,162.50	9,407.50
VIII	Tax expense / (credits)						
	(a) Current tax	988.10	856.30	470.50	1,844.40	861.60	2,274.40
	(b) Deferred tax	(100.40)	(114.20)	(622.90)	(214.60)	(664.20)	(1,048.30)
	(c) Current tax of prior period reversed	(91.70)	-	(11.40)	(91.70)	(11.10)	(23.20)
	Total tax expenses	796.00	742.10	(163.80)	1,538.10	186.30	1,202.90
IX	Profit after tax (VII-VIII)	2,136.40	2,447.00	2,446.60	4,583.40	3,976.20	8,204.60
X	Other comprehensive Income / (expenses)						
	Items that will not be reclassified to profit or loss						
	(a) Re-measurement gain / (loss) on defined benefits plans	(10.60)	(10.50)	(1.30)	(21.10)	(1.70)	(71.00)
	(b) Fair value gain / (loss) from investment in equity instruments (Refer note 5)	4,449.40	4,100.60	(3,423.40)	8,550.00	(5,704.60)	(4,835.80)
	(c) Income tax relating to items that will not be reclassified to profit or loss	(858.60)	-	-	(858.60)	-	-
	(d) Deferred tax relating to items that will not be reclassified to profit or loss	(184.60)	3.20	1.10	(181.40)	1.10	12.60
	Items that will be reclassified to profit or loss						
	(a) Exchange differences on translation of foreign operations	(882.80)	222.40	872.00	(660.40)	615.00	2,739.60
	(b) Exchange differences on net investment in foreign operations	(737.20)	(357.40)	30.40	(1,094.60)	(31.70)	(1,023.00)
	(c) Income tax relating to items that may be reclassified to profit or loss	-	-	-	-	-	-
	Total other comprehensive Income / (expenses) (net of tax)	1,776.60	3,958.30	(2,521.20)	5,733.90	(5,121.90)	(3,178.60)
XI	Total comprehensive income / (expenses), net of tax (IX+X)	3,912.00	6,405.30	(74.60)	10,317.30	(1,145.70)	5,026.00
	Profit attributable to:						
	- Owners of the Company	2,126.10	2,091.80	2,128.80	4,217.90	3,274.50	6,990.50
	- Non-controlling interest	10.30	355.20	317.80	365.50	701.70	1,214.10
	Other comprehensive Income / (expenses) attributable to:						
	- Owners of the Company	1,936.60	3,968.60	(2,572.40)	5,905.20	(5,147.60)	(3,197.50)
	- Non-controlling interest	(161.00)	(10.30)	51.20	(171.30)	25.70	18.90
	Total comprehensive Income / (expenses) attributable to:						
	- Owners of the Company	4,062.70	6,060.40	(443.60)	10,123.10	(1,873.10)	3,793.00
	- Non-controlling interest	(150.70)	344.90	369.00	194.20	727.40	1,233.00
XII	Equity share capital (face value of ₹ 2 each)	4,967.40	4,967.40	4,937.40	4,967.40	4,937.40	4,967.40
XIII	Other equity						69,308.60
XIV	Earnings per equity share: (face value of ₹ 2 each) (not annualised)						
	(1) Basic (in ₹)	0.86	0.85	0.88	1.71	1.35	2.87
	(2) Diluted (in ₹)	0.86	0.85	0.87	1.70	1.34	2.85
	See accompanying notes to the unaudited consolidated financial results						



Sequent

Proven Ability in Life Sciences
SEQUENT SCIENTIFIC LIMITED

UNAUDITED CONSOLIDATED BALANCE SHEET AS AT 30 SEPTEMBER 2020

(₹ in Lakhs)

Sl. No.	Particulars	As at	As at
		30-Sep-2020	31-Mar-2020
		Unaudited	Audited
(A)	ASSETS		
1	Non-current assets		
(a)	Property, plant and equipment	32,050.10	34,490.70
(b)	Capital work-in-progress	1,695.60	1,106.50
(c)	Goodwill	23,055.80	23,797.40
(d)	Other Intangible assets	4,210.40	4,934.50
(e)	Intangible assets under development	105.60	235.90
(f)	Financial assets		
	(i) Investments	5,944.40	13,128.80
	(ii) Other financial assets	656.10	680.30
(g)	Deferred tax assets (net)	2,228.90	2,324.00
(h)	Income tax assets (net)	576.90	568.10
(i)	Other non-current assets	273.90	150.30
	Total non current assets	70,797.70	81,416.50
2	Current assets		
(a)	Inventories	23,228.30	21,941.70
(b)	Financial assets		
	(i) Investments	17,118.80	4,017.90
	(ii) Trade receivables	30,617.60	31,876.40
	(iii) Cash and cash equivalents	12,100.80	6,809.60
	(iv) Bank balances other than (iii) above	350.50	772.90
	(v) Loans	33.00	34.80
	(vi) Others financial assets	1,931.40	1,015.30
(c)	Income tax assets (net)	31.30	72.70
(d)	Other current assets	3,245.90	3,872.40
		88,657.60	70,413.70
	Asset classified as held for sale (Refer note 9)	730.40	-
	Total current assets	89,388.00	70,413.70
	Total Assets	1,60,185.70	1,51,830.20
(B)	EQUITY AND LIABILITIES		
1	Equity		
(a)	Equity share capital	4,967.40	4,967.40
(b)	Other equity	69,859.90	69,308.60
(c)	Non-controlling interest	4,780.80	4,473.70
	Total equity	79,608.10	78,749.70
2	Liabilities		
I	Non-current liabilities		
(a)	Financial Liabilities		
	(i) Borrowings	12,940.00	15,005.90
	(ii) Other financial liabilities	4,167.40	6,684.30
(b)	Provisions	1,080.10	956.90
(c)	Deferred tax liabilities (net)	735.30	832.20
(d)	Other non-current liabilities	133.40	131.30
	Total non-current liabilities	19,056.20	23,610.60
II	Current liabilities		
(a)	Financial liabilities		
	(i) Borrowings	13,142.80	14,712.10
	(ii) Trade payables	21,217.40	22,038.00
	(iii) Other financial liabilities	21,634.70	8,814.00
(b)	Provisions	257.40	254.90
(c)	Current tax liabilities (net)	2,808.40	1,966.50
(d)	Other current liabilities	2,460.70	1,684.40
	Total current liabilities	61,521.40	49,469.90
	Total Equity and Liabilities	1,60,185.70	1,51,830.20
	See accompanying notes to the unaudited consolidated financial results		



Sequent

Proven Ability, In Life Sciences
SEQUENT SCIENTIFIC LIMITED

UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOW FOR SIX MONTHS ENDED 30 SEPTEMBER 2020

(₹ in Lakhs)

Particulars	Six months ended 30-Sep-2020	Six months ended 30-Sep-2019
	Unaudited	Unaudited
Cash flow from operating activities		
Net profit before tax and exceptional items	7,025.40	4,162.50
Adjustments for:		
Depreciation and amortisation expenses	2,633.00	2,447.60
Unrealised forex loss (net)	452.80	71.60
Bad trade receivables written off	249.60	0.80
Allowances for doubtful trade receivables	(219.00)	260.20
Finance costs	1,500.60	1,678.20
Dividend income	(77.40)	(526.50)
Interest income	(40.00)	(93.90)
Profit on sale of property, plant and equipment (net)	(9.90)	(18.90)
Profit on sale of investments (net)	(38.20)	(4.00)
Fixed assets written off	76.80	-
Lease liability written back (net)	(60.20)	-
Fair value gain on financial instruments at fair value through profit or loss	(110.50)	-
Share-based payments to employees	140.20	257.20
Operating profit before working capital changes	11,523.20	8,234.80
Changes in working capital		
(Increase) / decrease in trade receivables, loans and advances and other assets	(90.10)	(2,179.00)
(Increase) / decrease in inventories	(1,353.30)	(567.70)
Increase / (decrease) in margin money and unpaid dividend accounts	422.40	70.50
Increase / (decrease) in trade payables, other payables and provisions	(338.40)	(2,496.10)
Net changes in working capital	(1,359.40)	(5,172.30)
Cash generated from operations	10,163.80	3,062.50
Income taxes paid (net)	(1,730.60)	(279.90)
Net cash generated from operating activities (A)	8,433.20	2,782.60
Cash flow from investing activities:		
Purchase of property, plant and equipment and intangible assets	(1,779.50)	(1,936.60)
Proceeds from disposal of property, plant and equipment and intangible assets	103.00	56.10
Proceeds from sale of long term investments	15,734.40	-
(Purchase) / sale of current investments (net)	(13,055.50)	(247.50)
Interest received	29.30	87.00
Dividend received	71.20	526.50
Net cash generated from / (used in) investing activities (B)	1,102.90	(1,514.50)
Cash flow from financing activities		
Proceeds from issue of shares (including proceeds from stock options exercised by employees)	673.00	19.70
Proceeds from long-term borrowings	761.00	3,422.60
Repayment of long-term borrowings	(2,712.50)	(2,916.10)
Proceeds / (repayments) from / to short-term borrowings (net)	(1,570.90)	1,773.10
Interest and other borrowing cost paid	(1,350.20)	(1,640.60)
Dividend distributed to NCI	(46.70)	(94.20)
Equity contribution by NCI shareholders	1.40	3.90
Dividend paid	-	(485.60)
Dividend distribution tax paid	-	(97.00)
Net cash used in financing activities (C)	(4,244.90)	(14.20)
Net increase in cash and cash equivalents during the year (A+B+C)	5,291.20	1,253.90
Cash and cash equivalents at beginning of the year	6,809.60	6,778.90
Cash and cash equivalents at end of the year	12,100.80	8,032.80
See accompanying notes to the unaudited consolidated financial results		



Sequent
Proven Ability In Life Sciences
SEQUENT SCIENTIFIC LIMITED

Notes:

1. The above unaudited consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 06 November 2020. The statutory auditors have carried out the limited review of the above results.

2. The Group has only one reportable segment viz. Pharmaceuticals. Accordingly, no separate disclosure of segment information has been made.

3. Information on Standalone Results:

(₹ in Lakhs)

Particulars	3 months ended 30-Sep-2020	Preceding 3 months ended 30-Jun-2020	Corresponding 3 months ended in previous period 30-Sep-2019	Year to date figure for current period ended 30-Sep-2020	Year to date figure for previous period ended 30-Sep-2019	Previous year ended 31-Mar-2020
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Revenue from operations	6,964.10	5,924.40	5,152.00	12,888.50	10,324.00	22,733.30
Profit before tax	1,103.20	879.70	664.20	1,982.90	806.50	2,281.30
Profit after tax	921.43	691.20	1,018.41	1,612.63	1,160.71	2,134.14
Total comprehensive income / (expenses)	4,319.00	4,786.50	(2,404.49)	9,105.50	(4,542.29)	(2,724.06)

4. Following outbreak of COVID-19 pandemic globally and in India, the Group has adopted measures to curb the spread of infections in order to protect health of its employees and business continuity with minimal disruption. Considering that the Group is in business of Animal Health Care which is considered to be an essential service in all the countries, the Group has presence, the Group's operations have not been significantly impacted and all its plants are operating at normal capacity. The impact of the global health pandemic may be different from that estimated as at the date of approval of these unaudited consolidated financial results and the management will continue to closely monitor any material changes to future economic conditions.

5. Profit earned of ₹ 4,913.90 lakhs is transferred from other comprehensive income to reserves on sale of Investments classified at fair value through other comprehensive income.

6. Pursuant to Share Purchase Agreement (SPA) entered between Agnus Holdings Private Limited and other promoters and CA Harbor Investments (The Carlyle Group). The Carlyle Group has acquired 25.20% and 27.82% equity shares of the Company on 17 August 2020 and 08 September 2020 respectively. The above arrangement triggered an open offer and it was completed on 11 September 2020. The Carlyle Group currently holds 53.02% shareholding of the Company and has been classified as promoter of the Company.

7. During the quarter, the transfer of control to The Carlyle Group as explained in note 6 above, has resulted into following events --

(a) Accelerated vesting of unvested employee stock options and accordingly the Group has provided for this cost on an accelerated basis amounting to ₹ 309.30 lakhs.

(b) The Company has announced a one-time bonus to the existing employees not covered by ESOP Scheme of ₹ 212.00 lakhs.

(c) The Company has reviewed its operations in France and it has decided to wind up its operations. Accordingly, a provision of ₹ 382.60 lakhs has been considered representing ₹ 66.70 lakhs in inventory, ₹ 8.50 lakhs in receivables and ₹ 307.40 lakhs in intangible assets.

8. During the quarter, the Company has acquired additional 15% stake from minority shareholders of Fendigo BV, Netherland through Alivira Animal Health Limited, Ireland, wholly owned step down subsidiary of the Company, Pursuant to which, Fendigo BV is now wholly owned step down subsidiary of the Company.

9. The Company has entered into definitive agreement with minority shareholders for the acquisition of 40% stake in Provet Veteriner Urunleri San. Ve Tic. A. S., Turkey (Provet) through Alivira Animal Health Limited, Ireland, wholly owned step down subsidiary of the Company and said transaction has been completed on 02 November 2020. Pursuant to which, Provet is now wholly owned step down subsidiary of the Company. The excess of purchase consideration paid over the carrying value of non controlling interest (NCI) of ₹ 11,285.20 lakhs has been adjusted to reserves.

Further, as part of this agreement, a manufacturing facility having a carrying value of ₹ 730.40 lakhs has been agreed to be transferred to NCI and hence it is classified as asset held for sale.

10. The Australian Securities and Investment Commission, Australia vide letter dated 13 May 2020 has confirmed the strike off of Alivira Animal Health Australia Pty Ltd (step down foreign subsidiary). The impact of the same is immaterial in financial results.

11. The Code on Social Security, 2020 ('the Code') has been notified in the Official Gazette on 29 September 2020. The effective date from which the changes are applicable is yet to be notified and the rules are yet to be framed. Impact, if any, of the change will be assessed and accounted in the period in which the Code becomes effective and the rules framed thereunder are published.

12. During the quarter, the Group has recognised deferred tax credit of ₹ 311.00 lakhs in one of the subsidiary company on reassessment of unrecognised tax credit by applying annual effective tax rate.

13. The previous period figures have been regrouped wherever necessary to conform to current period's presentation.



For Sequent Scientific Limited

Manish
Manish Gupta
Managing Director

Place : Thane

Date : 06 November 2020

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
SeQuent Scientific Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of SeQuent Scientific Limited (the "Company") for the quarter ended September 30, 2020 and year to date from April 1, 2020 to September 30, 2020 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the **Standard on Review Engagements (SRE) 2410**, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For SRBC & CO LLP
Chartered Accountants
ICAI Firm registration number: 324982E/E300003



per Vikas Kumar Pansari
Partner
Membership No.: 093649
UDIN: 20093649AAAAC9666



Place: Mumbai
Date: November 6, 2020

Sequent

Prevent Ability in Life Sciences

SEQUENT SCIENTIFIC LIMITED

CIN: L99999MH1985PLC036685

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND PERIOD ENDED 30 SEPTEMBER 2020

(₹ In Lakhs)

SL No.	Particulars	3 months ended 30-Sep-2020	Preceding 3 months ended 30-Jun-2020	Corresponding 3 months ended In previous period 30-Sep-2019	Year to date figures for current period ended 30-Sep-2020	Year to date figures for previous period ended 30-Sep-2019	Previous year ended 31-Mar-2020
		UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
I	Revenue from operations	6,964.10	5,924.40	5,152.00	12,888.50	10,324.00	22,733.30
II	Other income	610.10	227.50	726.10	837.60	929.20	1,456.10
III	Total Income (I+II)	7,574.20	6,151.90	5,878.10	13,726.10	11,253.20	24,189.40
IV	Expenses						
	(a) Cost of materials consumed	2,897.00	2,482.50	2,531.91	5,379.50	5,084.95	10,869.10
	(b) Purchases of stock-in-trade	169.60	80.20	118.99	249.80	181.15	824.30
	(c) Changes in inventories of finished goods and work-in-progress	(268.40)	77.90	93.80	(190.50)	297.20	(389.20)
	(d) Conversion and processing charges	1,308.70	912.70	944.90	2,221.40	1,838.90	4,050.40
	(e) Employee benefits expense	550.10	525.70	428.60	1,075.80	771.60	1,709.70
	(f) Finance costs	72.70	110.10	119.10	182.80	261.10	503.50
	(g) Depreciation and amortisation expenses	216.40	216.40	222.80	432.80	445.40	895.00
	(h) Other expenses	1,260.10	866.70	753.80	2,126.80	1,566.40	3,445.30
	Total expenses	6,206.20	5,272.20	5,213.90	11,478.40	10,446.70	21,908.10
V	Profit before tax and exceptional items (III-IV)	1,368.00	879.70	664.20	2,247.70	806.50	2,281.30
VI	Exceptional items (Refer note 5)	264.80	-	-	264.80	-	-
VII	Profit before tax (V-VI)	1,103.20	879.70	664.20	1,982.90	806.50	2,281.30
VIII	Tax expense / (credits)						
	(a) Current tax	151.20	201.10	19.50	352.30	48.79	318.27
	(b) Deferred tax	122.30	(12.60)	(373.71)	109.70	(403.00)	(171.11)
	(c) Current tax of prior period reversed	(91.70)	-	-	(91.70)	-	-
	Total tax expenses	181.80	188.50	(354.21)	370.30	(354.21)	147.16
IX	Profit after tax (VII-VIII)	921.40	691.20	1,018.41	1,612.60	1,160.71	2,134.14
X	Other comprehensive Income / (expenses)						
	Items that will not be reclassified to profit or loss						
	(a) Re-measurements gain / (loss) on defined benefits plans	(7.50)	(7.40)	1.10	(14.90)	2.20	(29.70)
	(b) Fair value gain / (loss) from investment in equity instruments (refer note 6)	4,449.40	4,100.60	(3,423.40)	8,550.00	(5,704.60)	(4,836.80)
	(c) Income tax relating to items that will not be reclassified to profit or loss	(858.60)	-	-	(858.60)	-	-
	(d) Deferred tax relating to items that will not be reclassified to profit or loss	(185.70)	2.10	(0.60)	(183.60)	(0.60)	8.30
	Total other comprehensive Income/ (expenses) (net of tax)	3,397.60	4,095.30	(3,422.90)	7,492.90	(5,703.00)	(4,858.20)
XI	Total comprehensive Income / (expenses), net of tax (IX+X)	4,319.00	4,786.50	(2,404.49)	9,105.50	(4,542.29)	(2,724.06)
XII	Equity share capital (face value of ₹ 2 each)	4,967.40	4,967.40	4,937.40	4,967.40	4,937.40	4,967.40
XIII	Other equity						83,654.34
XIV	Earnings per equity share: (face value of ₹ 2 each) (not annualised)						
	(1) Basic (in ₹)	0.37	0.28	0.42	0.65	0.48	0.88
	(2) Diluted (in ₹)	0.37	0.28	0.42	0.65	0.47	0.87
	See accompanying notes to unaudited standalone financial results						



SEQUENT SCIENTIFIC LIMITED
UNAUDITED STANDALONE BALANCE SHEET AS AT 30 SEPTEMBER 2020

(₹ in Lakhs)

SL No.	Particulars	As at 30-Sep-2020	As at 31-Mar-2020
		Unaudited	Audited
A	ASSETS		
1.	Non-current assets		
(a)	Property plant and equipment	6,336.30	6,649.70
(b)	Capital work-in-progress	582.50	371.70
(c)	Intangible assets	226.60	291.50
(d)	Financial assets		
(i)	Investments		
(a)	Investments in subsidiaries	61,125.00	60,768.40
(b)	Other investments	5,942.30	13,126.80
(ii)	Loans	9,024.10	5,846.40
(iii)	Other financial assets	164.80	163.80
(e)	Deferred tax assets (net)	556.41	849.71
(f)	Income tax assets (net)	385.80	402.69
(g)	Other non-current assets	71.90	99.10
	Total non-current assets	84,415.71	88,569.80
2.	Current assets		
(a)	Inventories	3,243.20	3,141.90
(b)	Financial assets		
(i)	Investments	15,277.70	1,875.40
(ii)	Trade receivables	4,110.70	4,078.80
(iii)	Cash and cash equivalents	638.60	287.30
(iv)	Bank balances other than (iii) above	8.80	84.50
(v)	Loans	3.10	2.80
(vi)	Other financial assets	747.20	240.40
(c)	Other current assets	982.20	1,456.10
	Total current assets	25,011.50	11,167.20
	Total assets	1,09,427.21	99,737.00
B	EQUITY AND LIABILITIES		
I	Equity		
(a)	Equity share capital	4,967.40	4,967.40
(b)	Other equity	94,221.00	83,654.34
	Total equity	99,188.40	88,621.74
II	Liabilities		
1.	Non-current liabilities		
(a)	Financial liabilities		
(i)	Borrowings	1,240.60	1,516.50
(ii)	Other financial liabilities	36.00	44.10
(b)	Provisions	291.70	228.30
(c)	Other non current liabilities	22.30	30.10
	Total non-current liabilities	1,590.60	1,819.00
2.	Current liabilities		
(a)	Financial liabilities		
(i)	Borrowings	438.40	1,438.90
(ii)	Trade payables		
	Total outstanding dues of micro enterprises and small enterprises	678.90	417.02
	Total outstanding dues of creditors other than micro enterprises and small enterprises	5,466.21	6,016.64
(iii)	Other financial liabilities	644.50	825.10
(b)	Provisions	6.30	14.00
(c)	Current tax liabilities (net)	1,239.50	480.10
(d)	Other current liabilities	174.40	104.50
	Total current liabilities	8,648.21	9,296.26
	Total liabilities	10,238.81	11,115.26
	Total equity and liabilities	1,09,427.21	99,737.00
	See accompanying notes to unaudited standalone financial results		



Sequent

Proven Ability In Life Sciences

SEQUENT SCIENTIFIC LIMITED

UNAUDITED STANDALONE CASH FLOW STATEMENTS FOR SIX MONTHS ENDED 30 SEPTEMBER 2020

(₹ in Lakhs)

Particulars	Six months ended 30-Sep-2020	Six months ended 30-Sep-2019
	Unaudited	Unaudited
Cash flows from operating activities		
Net profit before tax and exceptional items	2,247.70	806.50
Adjustments for:		
Depreciation and amortisation expenses	432.80	445.40
Bad trade receivables written off	4.90	-
Allowances for doubtful trade receivables	(6.00)	-
Unrealised forex gain (net)	(112.80)	(3.20)
Finance costs	182.80	261.10
Dividend income	(77.30)	(526.40)
Fair value of corporate guarantee income	(4.50)	-
Interest income	(307.90)	(325.90)
Share-based payments to employees	65.00	62.20
Liabilities /provisions no longer required written back	-	2.60
Corporate guarantee commission	(26.30)	(25.90)
Fair value gain on financial instruments measured at fair value through profit or loss	(67.80)	-
Operating profit before working capital changes	2,330.60	696.40
Changes in working capital		
(Increase)/decrease in trade receivables, loans and advances and other assets	374.10	(73.00)
(Increase)/decrease in inventories	(101.30)	347.20
(Increase)/decrease in margin money and unpaid dividend accounts	75.70	(78.40)
Increase/(decrease) in trade payables, other payables and provisions	(386.00)	(570.60)
Net change in working capital	(37.50)	(374.80)
Cash generated by operations	2,293.10	321.60
Income taxes paid (net)	(336.80)	(95.50)
Net cash generated from operating activities (A)	1,956.30	226.10
Cash flows from investing activities		
Purchase of property, plant and equipments and intangible assets	(419.20)	(270.90)
Proceeds from disposal of property, plant and equipments and intangible assets	1.50	0.50
Purchase of current investments	(13,334.00)	-
Proceeds from sale of long term investments	15,734.40	-
Loan given to subsidiary company	(3,000.00)	-
Loan repaid by subsidiary company	96.00	500.00
Interest received	34.60	40.50
Dividend received	71.20	526.40
Net cash generated from / (used in) investing activities (B)	(815.50)	796.50
Cash flows from financing activities		
Proceeds / (repayment) from / to short-term borrowings (net)	(1,000.50)	171.90
Repayment of long-term borrowings	(296.70)	(127.20)
Proceeds from issue of shares (including proceeds from stock options exercised by employees)	673.00	19.70
Interest and other borrowing cost	(165.30)	(261.10)
Dividend paid	-	(485.60)
Dividend distribution tax paid	-	(97.00)
Net cash used in financing activities (C)	(789.50)	(779.30)
Net increase in cash and cash equivalents during the year (A+B+C)	351.30	243.30
Cash and cash equivalents at the beginning of the year	287.30	106.60
Cash and cash equivalents at the end of the year	638.60	349.90

See accompanying notes to unaudited standalone financial results



SEQUENT SCIENTIFIC LIMITED

Notes:

- 1 The above unaudited standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 06 November 2020. The statutory auditors have carried out limited review of the above results.
- 2 The Company has only one reportable segment viz. Pharmaceuticals. Accordingly, no separate disclosure of segment information has been made.
- 3 Following outbreak of COVID-19 pandemic globally and in India, the Company has adopted measures to curb the spread of infections in order to protect health of its employees and business continuity with minimal disruption. Considering that the Company is in business of Animal Health Care which is considered to be an essential service, the Company's operations have not been significantly impacted and its plants are operating at normal capacity. The impact of the global health pandemic may be different from that estimated as at the date of approval of these unaudited standalone financial results and the management will continue to closely monitor any material changes to future economic conditions.
- 4 Pursuant to Share Purchase Agreement (SPA) entered between Agnus Holdings Private Limited and other promoters and CA Harbor Investments (The Carlyle Group), The Carlyle Group has acquired 25.20% and 27.82% equity shares of the Company on 17 August 2020 and 08 September 2020 respectively. The above arrangement triggered an open offer and it was completed on 11 September 2020. The Carlyle Group currently holds 53.02% shareholding of the Company and has been classified as promoter of the Company.
- 5 During the quarter, the transfer of control to The Carlyle Group as explained in note 4 above, has resulted into following events –
(a) Accelerated vesting of unvested employee stock options and accordingly the Company has provided for this cost on an accelerated basis amounting to ₹ 128.00 lakhs.
(b) The Company has announced a one-time bonus to the existing employees not covered by ESOP Scheme of ₹ 136.80 lakhs.
- 6 Profit earned of ₹ 4,913.90 lakhs is transferred from other comprehensive income to reserves on sale of Investments classified at fair value through other comprehensive income.
- 7 The Code on Social Security, 2020 ('the Code') has been notified in the Official Gazette on 29 September 2020. The effective date from which the changes are applicable is yet to be notified and the rules are yet to be framed. Impact, if any, of the change will be assessed and accounted in the period in which the Code becomes effective and the rules framed thereunder are published.
- 8 The previous period figures have been regrouped wherever necessary to confirm to current period's presentation.



For Sequent Scientific Limited

Manish
Manish Gupta
Managing Director

Place : Thane

Date: 06 November 2020

Another quarter of Revenue and Margin momentum...

Q2 FY21 - Revenues at Rs. 3,463 Million up by 21.8%, EBITDA at Rs. 598 Million up 58.2%,

Mumbai, November 6, 2020

SeQuent Scientific Limited (SeQuent), which has businesses across Animal Health (Alivira) & Analytical Services today announced its financial results for the period ended September 30, 2020.

Consolidated Financial Highlights

	Rs. in millions					
	Q2 FY21	Q2 FY20	Growth (%)	H1 FY21	H1 FY20	Growth (%)
Revenues	3,463	2,842	21.8%	6,565	5,622	16.8%
EBITDA	598	378	58.2%	1,119	763	46.7%
EBITDA Margin %	17.3%	13.3%	400bps	17.0%	13.6%	340bps

Detailed presentation on the performance forms part of this press release.

Commenting on the Company's performance, **Manish Gupta, Managing Director** stated "The quarter gone by has laid the foundation for the next chapter in SeQuent's journey or 'SeQuent 2.0'. With Carlyle Group as new owners and a revamped Board with experienced professionals from diverse fields and global connects, we are both excited and confident as SeQuent gears up for the next-orbit of growth.

On the performance front, we are pleased to report another strong quarter across all key parameters with sales growth of 22% and EBITDA growth of 58%. With ROCE now in early twenties and cash from operations in excess of Rs. 1 Billion in the first half of FY21, our net debt stands reduced sharply, leading to a further upgrade in our credit rating.

None of this would have been possible without the unflinching commitment of our 1700+ workforce especially in these challenging times. We would like to thank our erstwhile and new shareholders for their support as we rewarded the employees in this ownership transition, which led to a one-off cost in the quarter.

We are confident that this momentum will continue to drive the business in the second half of this fiscal and the foreseeable future."

Earnings Call with Investors

The Company will conduct an Earnings call at **4:30 PM IST on November 6, 2020** where the Management will discuss the Company's performance and answer questions from participants. To participate in this conference call, please dial the numbers provided below ten minutes ahead of the scheduled start time. The dial-in numbers for this call are **+91 22 6280 1263 or +91 22 7115 8213**.

About SeQuent Scientific Limited

SeQuent Scientific Limited (BSE-512529, NSE-SEQUENT) headquartered in Mumbai, India with a global footprint, operates in the domains of Animal Health (Alivira) and Analytical Services. SeQuent has eight manufacturing facilities based in India, Spain, Germany, Brazil and Turkey with approvals from global regulatory bodies including USFDA, EUGMP, WHO, TGA among others. Its Vizag facility is India's first and only USFDA approved facility for veterinary APIs.

For details, feel free to contact:

Tushar Mistry

Chief Financial Officer Tel: +91 22 4111 4717

tushar.m@sequent.in

Diwakar Pingle

Christensen Investor Relations Tel : +91 22 4215 0210

dpingle@christensenir.com

Abhishek Singhal

Investor Relations Consultants abhishek.s@sequent.in

Registered Office

301/A, 'Dosti Pinnacle', Plot No. E7, Road No. 22,
Wagle Industrial Area, Thane (W), Maharashtra, India CIN:


L99999MH1985PLC036685

BSE Code:512529 | NSE: SEQUENT

ISIN: INE807F01027 | REUTERS: EQU.BO

Websites: www.sequent.in

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward- looking statements. SeQuent Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.




Earnings Presentation

Q2 & H1FY21

November 6, 2020

Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "plan", "contemplate", seek to", "future", "objective", "goal", "likely", "project", "should", "potential", "will pursue", and similar expressions of such expressions may constitute "forward-looking statements". These forward looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.





**Managing Director,
Manish Gupta**

“The quarter gone by has laid the foundation for the next chapter in SeQuent’s journey or ‘SeQuent 2.0’. With Carlyle Group as new owners and a revamped Board with experienced professionals from diverse fields and global connects, we are both excited and confident as SeQuent gears up for the next-orbit of growth.

On the performance front, we are pleased to report another strong quarter across all key parameters with sales growth of 22% and EBITDA growth of 58%. With ROCE now in early twenties and cash from operations in excess of ₹ 1 Billion in the first half of FY21, our net debt stands reduced sharply, leading to a further upgrade in our credit rating.

None of this would have been possible without the unflinching commitment of our 1700+ workforce especially in these challenging times. We would like to thank our erstwhile and new shareholders for their support as we rewarded the employees in this ownership transition, which led to a one-off cost in the quarter.

We are confident that this momentum will continue to drive the business in the second half of this fiscal and the foreseeable future. ”





Focus

Transitioned from multi-business model to a focused, pure-play animal health business



Scale

Established scale in the chosen business to emerge as India's largest and now amongst 'Top 20' global animal health companies



Capability

Comprehensive capabilities across APIs and Formulations - front-end presence in key markets, global manufacturing (incl. India's first USFDA approved facility), R&D & management team. Strong framework of governance and compliance



Financials

Transformation across key financial parameters – mid-teen EBITDA margin, low leverage of 0.2, ROCEs in early 20s and robust cash flows leading to a 6 step improvement in credit rating



Rewiring SeQuent for the next orbit in progress..

Focus on operational excellence and relentless execution has ensured consistent financial outcomes in current challenging times

Delivering focused financial outcomes



Ownership Change



Reconstitution of the Board with a more global representation under the aegis of the new promoters, The Carlyle Group

Internal corporate realignment with consolidation of shareholding in Turkey & Netherlands

Consolidation of Minority Holdings



Management Continuity



Existing management to drive the future strategy thereby ensuring continuity





Key Corporate Developments



The Carlyle Group assumes charge as the new promoter...



Change of control

Carlyle acquired 25.20% and became the new Promoter on August 17, 2020 and acquired additional 27.82% on September 8, 2020



Industry leaders join the Board

Dr. Kamal Sharma, Non-Executive Chairman & Mr. Milind Sarwate appointed as Independent Directors



Induction of Carlyle nominees

Mr. Neeraj Bharadwaj, Mr. Rahul Mukim & Mr. Gregory John Andrews join the Board as Carlyle nominees



...prompting a broad-basing of the Board with global outlook




Dr. Kamal K Sharma
Independent Director
Non-Executive Chairman

- BE-IITK; PGDIM-JBIMS; PhD-IIT Mum.
- 48 years CXO experience
- Expertise in creating & leading large chemical and pharmaceutical companies



Mr. Milind Sarwate
Independent Director

- ACA, ACS, ACMA, B Com, CII-Fulbright Fellow
- 37 years' experience- incl CFO, CHRO roles
- Independent Directorship in listed & unlisted Cos
- Expertise in value creation, effective governance & capability building



Dr. Kausalya Santhanam
Independent Director

- M.Sc; Ph.D; LLB (Intellectual Property)
- Registered Patent Agent
- Patent law practitioner with US in-house experience in biopharmaceutical industry.



Mr. Neeraj Bharadwaj
Non-Executive Director
(Carlyle Nominee)

- BS-Wharton; MBA-Harvard
- MD, Carlyle India
- Expertise in large growth capital & buyout opportunities



Mr. Gregory John Andrews
Director
(Carlyle Nominee)

- BSc (Hons); PGDBM
- Animal health consultant in USA & France
- 30 years CXO experience in animal health



Mr. Rahul Mukim
Non-Executive Director
(Carlyle Nominee)


- BE-VJTI; MBA-IIM Lucknow
- Director, Carlyle India
- Expertise in buyout opportunities, healthcare growth investment



Ownership structure



Shareholding as on 30 th September 2020	(% of Total Equity)
Carlyle	53.0%
FPI	8.4%
DII	10.1%
Others	28.5%

Nil shares pledged as on September 30, 2020





Unlocking Value Creation



Consolidation of Subsidiaries

Provet

- ⌚ Amongst the top 3 and the largest local veterinary medicines company in Turkey having market share of ~10% with more than 120 product registrations
- ⌚ 8 manufacturing lines in various dosage forms including injectables, oral solutions, aerosols and intrauterine
- ⌚ Caters to bacterial, parasitic, anthelmintic, antiparasitic, nutritional for the ruminant therapeutics segment
- ⌚ Acquired 40% of Provet making it a wholly owned subsidiary

Fendigo

- ⌚ Netherlands based veterinary marketer for pets, farm animals, horses and poultry health products
- ⌚ Acquired 15% of Fendigo making it a wholly owned subsidiary


Source of Funds

Consolidation funded by sale of treasury holding in Strides Pharma Science Limited




... supplemented by a Credit Rating Upgrade


- ⑥ India Ratings upgraded long term credit rating of SeQuent from IND A- (Stable) to **IND A (Positive)**
- ⑥ Consistent financial performance and debt reduction lead to 6 step improvement over last 5 years
- ⑥ Confidence in strength of business model with diversified revenue mix underpinned with relentless focus on execution making SeQuent amongst the 'Top 20' animal health industry players globally
- ⑥ Further facilitated by the financial and global strength of the new promoters – 'Carlyle Group'
- ⑥ Alivira Animal Health Limited credit rating also upgraded from IND A- (Stable) to **IND A (Positive)**



... foundations in place for Sequent 2.0



Successfully Negotiating the Covid Storm



- ⑥ Collaborative efforts to maintain eco-system & manage stakeholders with larger interest in mind
 - ⑥ Complete support to vendors & employees, timely payments to all including banks
 - ⑥ Enhanced medical insurance coverage across the organisation
- ⑥ Operations continued across all sites in India and overseas under heightened care
- ⑥ Supply chain team support ensured availability of materials despite significant logistical challenges
- ⑥ Field operations was streamlined for safety, field visits replaced by phone calls to customers
- ⑥ Extra-ordinary co-ordination between Marketing, Operations, Finance and HR ensured near execution of the plan across the three quarters



India

- ⑥ Mahad operations suspended for 10 days in Q2 FY21 due to Covid cases in the region;
- ⑥ No perceptible impact on other sites with stray Covid cases
- ⑥ Vizag plant expansion project extended by 3 months

EU




- ⑥ Prioritisation of plant operations by diverting technical resources from R&D to QC operations
- ⑥ Building safety inventories for possible supply chain disruptions
- ⑥ Bremer capex plans deferred to next year due to execution challenges

Other Location

- ⑥ All operations continue unaffected in both Brazil and Turkey with sound safety measures in place



... while delivering strong financials




*Adjusted PAT accounting for one-off cost





Q2 FY21 and H1 FY21 Performance Review



Another quarter of Revenue and Margin momentum...

	Q2 FY21		YoY	H1 FY21		YoY
Revenues	Q2 FY21	3,463	21.8%	H1 FY21	6,565	16.8%
	Q2 FY20	2,842		H1 FY20	5,622	
EBITDA	Q2 FY21	598	58.2%	H1 FY21	1,119	46.7%
	Q2 FY20	378		H1 FY20	763	
Adjusted PAT*	Q2 FY21	297	39.4%	H1 FY21	506	28.8%
	Q2 FY20	213		H1 FY20	327	
Cash from Operations	Q2 FY21	607	2.8x	H1 FY21	1,016	3.3x
	Q2 FY20	218		H1 FY20	306	

*Adjusted PAT accounting for one-off cost



Strong performance across businesses drives new revenue peak

All values in ₹ Mn

Revenue Distribution	Q2'21	Q2'20	YoY%	YoY% (Constant currency)	H1'FY21	H1,FY20	YoY%	YoY% (Constant currency)
Formulations	2,263	1,869	21.1%	24.7%	4,264	3,743	13.9%	16.5%
<i>Europe</i>	952	844	12.8%	1.6%	2,028	1,726	17.5%	7.7%
<i>Turkey</i>	400	325	23.1%	48.5%	757	668	13.3%	28.9%
<i>Emerging Markets</i>	558	429	30.0%	25.2%	7942	837	(5.3%)	(8.2%)
<i>LATAM</i>	353	271	30.3%	67.3%	687	512	34.2%	70.5%
APIs	1,200	973	23.3%	18.3%	2,301	1,880	22.4%	20.2%
Global Sales	3,463	2,842	21.8%	22.5%	6,565	5,622	16.8%	17.8%

Key Highlights



Revenues breach ₹3.4bn (+22.5%), up 10% over previous peak

- Formulations drives growth for the quarter, +24.7%
- Strong performance across key geographies of Latam and Turkey
- India drives strong recovery in Emerging Markets
- API Business: Highest quarterly sales of ₹1,200Mn, +18.3%

Note: All growth % are in constant currency



Q2 & H1FY21 Business Review



Formulations Continue to Create Value...

Highlights

- ⦿ Outperformance continues in Brazil and Turkey with new product launches coupled with market share gains for existing products
- ⦿ Benelux drives EU, Spain subdued in the quarter
- ⦿ Strong recovery in India, commercialised Zoetis products in India, achieve 2x scale
- ⦿ Cautious approach continue for rest of Emerging markets
- ⦿ EU approvals received for:
 - ⦿ World's largest injectable filing within 11 months of filing
 - ⦿ 3 products approvals from Spain's R&D development
 - ⦿ Commercialisation to drive H2 performance

All values in ₹ Mn

Q2FY21	Q2FY20	YoY% (cc)	H1 FY21	H1 FY20	YoY% (cc)
2,263	1,869	24.7%	4,264	3,743	16.5%

FDFs

1000+

Manufacturing facilities

5

Sales to regulated markets

65%+

Countries with marketing presence

80+



... While APIs scale the Capability Curve

Highlights

- ⦿ Highest quarterly sales of ₹1,200Mn with a growth of 18.3%
- ⦿ CDMO model initiated with one of the largest AH player – 2 products under execution
- ⦿ 1 USVMF filing in the quarter, 20 US filings in total,
- ⦿ Enhanced production capacity at Mahad, Vizag expansion to be completed in Q4

All values in ₹ Mn

Q2FY21	Q2FY20	YoY% (cc)	H1 FY21	H1 FY20	YoY% (cc)
1,200	973	18.3%	2,301	1,880	20.2%

Commercial APIs

27

Manufacturing facilities

3

Sales to regulated markets

75%+

Asset turnover ratio

2.5x



Formulations

Products Under Development

35+

R&D Centres

4

Injectables

38%

New filings in US next 3 years

10

API

Molecules in pipeline

14+

R&D Centre

1

US Filings

20

CEP Filings

11





Financials



Strong Consolidated Financials trend continues ...

PARTICULARS	Q2 FY21 Unaudited	Q1 FY21 Unaudited	Q2 FY20 Unaudited	H1 FY21 Unaudited	H1 FY20 Unaudited	FY20 Audited
Revenue from Operations	3,463	3,103	2,842	6,565	5,622	11,792
Material Consumption	(1,807)	(1,594)	(1,508)	(3,401)	(2,939)	(6,051)
Gross Margin	1,656	1,508	1,335	3,164	2,684	5,742
%	47.8%	48.6%	47.0%	48.2%	47.7%	48.7%
Operating Expenses	(1,058)	(987)	(957)	(2,045)	(1,921)	(3,984)
EBITDA	598	521	378	1,119	763	1,758
%	17.3%	16.8%	13.3%	17.0%	13.6%	14.9%
Exchange Gain / (Loss)	(34)	(11)	(6)	(45)	(7)	(55)
Other Income	26	15	60	42	73	101
Finance Cost	(74)	(76)	(78)	(150)	(168)	(357)
Depreciation	(133)	(130)	(125)	(263)	(245)	(506)
Exceptional Items	(90)	-	-	(90)	-	-
Earnings Before Tax	293	319	228	612	416	941
Taxes	(80)	(74)	16	(154)	(19)	(120)
Earnings After Tax	214	245	245	458	398	820
Minority Interest	1	36	32	37	70	121
Earnings after Minority Interest	213	209	213	422	327	699
Earnings per share ₹	0.86	0.85	0.87	1.70	1.34	2.85



...adjusted PAT for one-off cost

Excluding the one-time non-recurring expenses, the Normalised PAT is:

PARTICULARS	Q2 FY21 Unaudited	Q1 FY21 Unaudited	Q2 FY20 Unaudited	H1 FY21 Unaudited	H1 FY20 Unaudited	FY20 Audited
Reported PAT (including exceptional items)	213	209	213	423	327	699
Non-recurring expenses (net of tax)	84	-	-	84	-	-
Adjusted PAT	297	209	213	506	327	699


Break-up of Non-recurring expenses:	Amount
One-time Bonus to employees & Accelerated vesting of ESOPs on change of control	52.1
Alivira France operations discontinued due to adverse business environment	38.3
Total	90.4




... resulting in a strong Balance Sheet, and

All values in ₹Mn

Particulars	Sep-20	Mar-20
Shareholders Funds	7,483	7,428
Minority Interest	478	447
Net Debt*	1,496	2,282
Investments	594	1,313
Tangible Assets	3,375	3,560
Intangible Assets	2,737	2,897
Working Capital	3,042	3,127



*H1 Annualized





*Net Debt considers payout for consolidation of Turkey



Balance Sheet Highlights

- ⑥ Focus on profitability resulting in strong cash flow from operations
- ⑥ Cash flow generation aids net debt reduction and lower gearing
- ⑥ Well integrated acquisitions with a focus on front end formulation business leading to higher return ratios
- ⑥ Judicious capital allocation leading to scale up in ROCE



FY21 Delivering on guidance



FY21 Outlook

- High-teen revenue growth
- 200+ bps margin expansion



H1FY21 status

- 16.8% revenue growth
- 340 bps margin expansion



Thank You



For details, feel free to contact:

Tushar Mistry

Chief Financial Officer

+91 22 4111 4717
tushar.m@sequent.in

Diwakar Pingle

Christensen Investor Relations

+91 22 4215 0210
dpingle@christensenir.com

Abhishek Singhal

Investor Relations Consultant

abhishek.s@sequent.in

Registered Office: 301/A, 'Dosti Pinnacle', Plot No. E7, Road No. 22, Wagle Industrial Area, Thane (W), Maharashtra, India

Websites: www.sequent.in, www.alivira.co | CIN: L99999MH1985PLC036685 | BSE Code:512529 | NSE: SEQUENT | ISIN: INE807F01027

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. SeQuent Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

